CMS' Amyvid decision on the horizon

05/20/2013 | MolecularImaging.net

Eli Lilly & Co. and Avid Pharmaceuticals, the makers of the Alzheimer's imaging agent Amyvid, recently discussed the upcoming CMS draft decision on reimbursement for Amyvid and similar agents. Wei-Li Shao, senior director of Lilly's Alzheimer's business division, discussed three possible coverage decisions: continued non-coverage, coverage of amyloid PET imaging in full or coverage with evidence development. Shao said the decision could come between late June and the end of July. The companies said various groups including SNMMI have expressed support for CMS coverage.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI